Phase 2 PTSD Trial, Recruiting NCT06577636 Sponsor: Stanford University Condition: PTSD
Back to Ptsd

Phase 2 PTSD Trial, Recruiting

NCT06577636
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old (male or female)
  • You are able to read, understand, and sign a consent form before the study begins
  • You have been diagnosed with PTSD, confirmed through a structured interview with trained study staff
  • Your PTSD symptoms score above a certain level on a standard assessment called the CAPS-5 (confirm with trial site)
  • You are in generally good health, considered low-risk for a minor procedure (roughly meaning no serious ongoing health conditions)
  • If you are female, you are either unable to become pregnant or are using an accepted form of birth control
  • Your body weight is within a moderate range relative to your height (BMI between 17 and 35)

Who may not be able to join:

  • You are pregnant or currently breastfeeding
  • Your PTSD symptoms score at or below 20 on the CAPS-5 assessment
  • You currently have a moderate or severe substance use or alcohol use disorder (mild cases, cases in remission, or nicotine dependence may still be eligible — confirm with trial site)
  • You currently have certain other mental health diagnoses beyond PTSD, particularly if they are the main focus of your treatment or are not well-managed (confirm with trial site for specifics)
  • You have a history of schizophrenia, schizoaffective disorder, or any episodes of psychosis
  • You have had anorexia nervosa, bulimia nervosa, or another eating disorder within the past five years
  • Another mental health condition is currently more significant than your PTSD, or has been within the past six months
  • The study team believes you may be at significant risk of suicidal behaviour during the study
  • You have a neurological disorder (a condition affecting the brain or nervous system)
  • You have a cardiovascular disorder (a heart or blood vessel condition)
  • You have a pulmonary or respiratory disorder (a lung or breathing condition)
  • You have significant liver disease
  • You have significant kidney disease
  • You have acid reflux, a hiatal hernia, or another digestive condition that could pose a risk during a procedure
  • You have an endocrine disorder (a condition affecting hormones, such as an uncontrolled thyroid condition — confirm with trial site)
  • You have abnormal lab results at screening that the study doctor considers a safety risk
  • Your current mental health provider believes the study would pose a risk to you
  • You are currently participating in, or have recently taken part in, another clinical trial involving an investigational drug or device that may conflict with this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Boris D Heifets, MD, PhD, Stanford University

Phone: (669) 241 6118

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 July 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov